(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 November 2011 (03.11.2011)

PCT

(10) International Publication Number
WO 2011/137395 A1

(51) International Patent Classification:
C07K 16/18 (2006.01)

(21) International Application Number:
PCT/US2011/034672

(22) International Filing Date:
29 April 2011 (29.04.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/330,260 30 April 2010 (30.04.2010) US
61/471,465 4 April 2011 (04.04.2011) US

(72) Inventors; and
(71) Applicants : **ROTHER, Russell, P.** [US/US]; 10325 Forest Meadow Drive, Oklahoma City, OK 73151 (US). **SHERIDAN, Douglas, L.** [US/US]; 92 Limewood Avenue C5, Branford, CT 06405 (US). **TAMBURINI, Paul, P.** [US/US]; 80 Devonshire Way, Kensington, CT 06037 (US). **ZHANG, Yuchun** [CA/US]; 440 Budding Ridge Road, Cheshire, CT 06410 (US).

(74) Agents: **VARMA, Anita** et al.; Ropes & Gray LLP, Prudential Tower, 800 Boylston Street, Boston, MA 02199 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,

[Continued on next page]

(54) Title: ANTI-C5A ANTIBODIES AND METHODS FOR USING THE ANTIBODIES

(57) Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.




Fig. 1

WO 2011/137395 A1

ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*